Page last updated: 2024-11-11
ascladiol
Description
ascladiol: direct precursor of patulin biosynthesis in Penicillium urticae [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
(E)-ascladiol : A butenolide that is furan-2(5H)-one which is substituted by a hydroxymethyl group at position 4 and a 2-hydroxyethylidene group at position 5 (the 5E isomer). A direct precursor of patulin in cell-free preparations of Penicillium urticae patulin-minus mutants J1 and S11, but not S15. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (12)
Synonym |
ascladiol |
(e)-ascladiol |
(5e)-5-(2-hydroxyethylidene)-4-(hydroxymethyl)furan-2(5h)-one |
CHEBI:145112 |
81183-44-0 |
(5e)-5-(2-hydroxyethylidene)-4-(hydroxymethyl)furan-2-one |
2(5h)-furanone, 5-(2-hydroxyethylidene)-4-(hydroxymethyl)- |
32013-85-7 |
ascladiol, (e)- |
2R4H5L9HF9 , |
unii-2r4h5l9hf9 |
Q27891367 |
Roles (1)
Role | Description |
mycotoxin | Poisonous substance produced by fungi. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (2)
Class | Description |
butenolide | A gamma-lactone that consists of a 2-furanone skeleton and its substituted derivatives. |
primary allylic alcohol | An allylic alcohol in which the carbon atom that links the double bond to the hydroxy group is also attached to two hydrogens. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (11)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 1 (9.09) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (27.27) | 29.6817 |
2010's | 5 (45.45) | 24.3611 |
2020's | 2 (18.18) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 11 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |